Application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament

A herpes simplex virus, herpes virus technology, applied in the field of pharmacology, can solve the problem of no sulfate resistance and other problems

Inactive Publication Date: 2014-04-30
GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From the first extract of antiviral active substances from seaweed in 1958, to the discovery in the 1980s that synthetic and semi-synthetic polysaccharide sulfates are effective inhibitors of HIV replication, and now it is discovered that polysaccharide sulfates inhi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament
  • Application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament
  • Application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: Preparation of Eucheuma polysaccharide

[0020] Weigh a certain amount of Eucheuma aegerina, crush the washed Eucheuma aeruginosa (so that the water content does not exceed 8%) with a pulverizer, soak the pulverized Eucheuma aeruginosa for 0.5h, and then use a heating Reflux device for hot water extraction of polysaccharides for 3 hours, after cooling to about 40°C, collect the filtrate, use a rotary evaporator to concentrate the filtrate to 2 / 3 of the volume of the original filtrate, then directly add 3 times the volume of 95% ethanol, and keep stirring , placed in a refrigerator at 4°C for alcohol precipitation for 12 hours, filtered through four layers of gauze, collected the filtrate, and freeze-dried after the residual alcohol was partially volatilized. figure 1 shown.

Embodiment 2

[0021] Example 2: Cytotoxicity study of Eucheuma polysaccharide

[0022] The obtained Eucheuma polysaccharide was prepared into a 1 mg / mL aqueous solution with pure water, and stored at -20°C for later use.

[0023] Eucheuma polysaccharide was diluted to different concentrations (initial concentration was 500 μg / mL), and the cytotoxicity of Eucheuma polysaccharide was determined by MTT method.

[0024] MTT experimental results (see figure 2 ) showed that the survival rate of Vero cells was 74.85% when the concentration of Eucheuma polysaccharide (EGP) reached 500 μg / mL, and the survival rate of Vero cells was 79.41% when the positive control drug acyclovir (ACV) was 500 μg / mL. It can be seen that Eucheuma polysaccharide and acyclovir have very little toxicity to Vero cells, and their respective TC50 values ​​are all >500g / mL. Example 3: Anti-herpes simplex virus HSV drug effect research of Eucheuma polysaccharide

Embodiment 3

[0024] MTT experimental results (see figure 2 ) showed that the survival rate of Vero cells was 74.85% when the concentration of Eucheuma polysaccharide (EGP) reached 500 μg / mL, and the survival rate of Vero cells was 79.41% when the positive control drug acyclovir (ACV) was 500 μg / mL. It can be seen that Eucheuma polysaccharide and acyclovir have very little toxicity to Vero cells, and their respective TC50 values ​​are all >500g / mL. Example 3: Anti-herpes simplex virus HSV drug effect research of Eucheuma polysaccharide

[0025] a. According to the method of Example 1, Eucheuma polysaccharide was extracted from Eucheuma agaricus, the average molecular weight was 45000, and the degree of substitution of monosaccharide sulfate groups was 2.13.

[0026] b. The Eucheuma polysaccharide prepared in step a. was prepared into a dilution solution with an initial concentration of 62.5 μg / mL with reference to the results of the cytotoxicity test in Example 2, and the anti-herpes simp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament. The Eucheuma gelatinae polysaccharide has mean molecular weight of 1,000-100,000. The Eucheuma gelatinae polysaccharide provided by the invention has independent anti-herpes simplex virus effect.

Description

technical field [0001] The invention belongs to the field of pharmacology, and relates to the application of polysaccharide sulfate as a drug for preparing anti-herpes simplex virus. In particular, it relates to the application of Eucheuma polysaccharide and a-D-(1-6)-glucose sulfate as preparation of anti-herpes simplex virus drugs. technical background [0002] Herpesviridae (Herpesviridae) is divided into three subfamilies: α-herpesviridae, β-herpesviridae and γ-herpesviridae. Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are human herpesvirus type 1 (HHV-1) and type 2 (HHV-2), both viruses belong to the family Herpesviridae, Alphaherpesvirus Subfamily, herpes simplex virus genus, and have a high degree of similarity in virus structure, proliferation mechanism and other aspects. [0003] Herpes simplex virus (HSV) is a neurotropic virus that can invade the central nervous system and destroy the structure and function of nerve cells. Among them, HSV-1 is an imp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/715A61K31/737A61P31/22C08B37/00
Inventor 王一飞王怀玲金富军利奕成刘秋英
Owner GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap